Tag: IBX

Diagnostic imaging medical technology ASX stocks Xray CT MRI

Diagnostic imaging: which stock will become the next Pro Medicus?

For all the leaps and bounds in medical science, the know-how behind detecting diseases hasn’t changed much in decades – or even centuries. Take X-rays, which are widely used despite the wee proble...
Imagion Biosystems ASX IBX nanoparticles enhance MRI images reduce costs

Imagion Biosystems’ nanoparticles could enhance MRI images and reduce costs

Research by the University of Sydney has demonstrated that iron oxide nanoparticles developed by Imagion Biosystems (ASX: IBX) can enable low-field magnetic resonance imaging and could potentially red...
Imagion Biosystems ASX IBX Siemens Healthineers MagSense nanoparticles MRI contrast agent HER2

Imagion Biosystems signs Siemens deal to advance cancer detection technology in MRIs for breast cancer patients

Cancer detection company Imagion Biosystems (ASX: IBX) has signed a collaboration agreement with global medical technology firm Siemens Healthineers to explore the use of Imagion’s MagSense nanopartic...
Imagion Biosystems ASX IBX breakthrough device designation FDA MagSense HER2 breast cancer

Imagion Biosystems receives FDA breakthrough designation for breast cancer detection device

Imagion Biosystems (ASX: IBX) has received notification from the Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) that the MagSense System and Test for stagi...
Imagion Biosystems ASX IBX clinical development stage HER2 breast cancer detection reagent

Imagion Biosystems enters clinical development stage of HER2 breast cancer detection reagent; in vivo study in 2019

Cancer detection innovator Imagion Biosystems (ASX: IBX) has announced it will proceed to clinical development of a nanoparticle test reagent designed to enable early identification of HER2 cells in t...